IQVIA Seen Benefiting From Clinical Trial Rebound Through 2026 on AI Strength, RBC Says

MT Newswires Live03-04

IQVIA (IQV) is "well positioned" to benefit from a projected rise in clinical trial activity through 2026, due to its large "proprietary data" assets, strong pharma relationships, and advantages in real-world evidence and artificial intelligence-driven analytics, RBC Capital Markets said in a report emailed Tuesday.

The brokerage cited numerous indicators pointing to an acceleration in clinical trial activity into 2026, signaling an "inflection" in the contract research organization market, adding that IQVIA's scale and "differentiated" analytics capabilities give it a "competitive edge" as activity rebounds.

The firm highlighted IQVIA's database of about "1.2 billion patient records" and more than 64 petabytes of proprietary data, which it said can enhance clinical trial design, site selection and patient recruitment. As real-world evidence, or RWE, becomes increasingly embedded in clinical studies, RBC believes IQVIA's data advantage will be a key driver of outperformance.

RBC initiated coverage of IQVIA with an outperform rating and a $221 price target.

Price: 170.38, Change: -3.89, Percent Change: -2.23

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616322583?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-04 00:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616322583","market":"us","top_or_hot":-1,"title":"IQVIA Seen Benefiting From Clinical Trial Rebound Through 2026 on AI Strength, RBC Says","media":"MT Newswires Live","content":"<html><body><p> IQVIA (IQV) is \"well positioned\" to benefit from a projected rise in clinical trial activity through 2026, due to its large \"proprietary data\" assets, strong pharma relationships, and advantages in real-world evidence and artificial intelligence-driven analytics, RBC Capital Markets said in a report emailed Tuesday.</p><p>The brokerage cited numerous indicators pointing to an acceleration in clinical trial activity into 2026, signaling an \"inflection\" in the contract research organization market, adding that IQVIA's scale and \"differentiated\" analytics capabilities give it a \"competitive edge\" as activity rebounds.</p><p>The firm highlighted IQVIA's database of about \"1.2 billion patient records\" and more than 64 petabytes of proprietary data, which it said can enhance clinical trial design, site selection and patient recruitment. As real-world evidence, or RWE, becomes increasingly embedded in clinical studies, RBC believes IQVIA's data advantage will be a key driver of outperformance.</p><p>RBC initiated coverage of IQVIA with an outperform rating and a $221 price target.</p><p>Price: 170.38, Change: -3.89, Percent Change: -2.23</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IQVIA Seen Benefiting From Clinical Trial Rebound Through 2026 on AI Strength, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIQVIA Seen Benefiting From Clinical Trial Rebound Through 2026 on AI Strength, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-04 00:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> IQVIA (IQV) is \"well positioned\" to benefit from a projected rise in clinical trial activity through 2026, due to its large \"proprietary data\" assets, strong pharma relationships, and advantages in real-world evidence and artificial intelligence-driven analytics, RBC Capital Markets said in a report emailed Tuesday.</p><p>The brokerage cited numerous indicators pointing to an acceleration in clinical trial activity into 2026, signaling an \"inflection\" in the contract research organization market, adding that IQVIA's scale and \"differentiated\" analytics capabilities give it a \"competitive edge\" as activity rebounds.</p><p>The firm highlighted IQVIA's database of about \"1.2 billion patient records\" and more than 64 petabytes of proprietary data, which it said can enhance clinical trial design, site selection and patient recruitment. As real-world evidence, or RWE, becomes increasingly embedded in clinical studies, RBC believes IQVIA's data advantage will be a key driver of outperformance.</p><p>RBC initiated coverage of IQVIA with an outperform rating and a $221 price target.</p><p>Price: 170.38, Change: -3.89, Percent Change: -2.23</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2616322583","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616322583","pubTimestamp":1772554216,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"IQVIA  is \"well positioned\" to benefit from a projected rise in clinical trial activity through 2026, due to its large \"proprietary data\" assets, strong pharma relationships, and advantages in real-world evidence and artificial intelligence-driven analytics, RBC Capital Markets said in a report emailed Tuesday.The brokerage cited numerous indicators pointing to an acceleration in clinical trial activity into 2026, signaling an \"inflection\" in the contract research organization market, adding that IQVIA's scale and \"differentiated\" analytics capabilities give it a \"competitive edge\" as activity rebounds.The firm highlighted IQVIA's database of about \"1.2 billion patient records\" and more than 64 petabytes of proprietary data, which it said can enhance clinical trial design, site selection and patient recruitment. As real-world evidence, or RWE, becomes increasingly embedded in clinical studies, RBC believes IQVIA's data advantage will be a key driver of outperformance.RBC initiated cove","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","LU0130103400.USD":"Natixis Harris Associates Global Equity RA USD","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0648001328.SGD":"Natixis Harris Associates US Equity RA SGD","LU1201861165.SGD":"Natixis Harris Associates Global Equity PA SGD","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU1201861249.SGD":"Natixis Harris Associates US Equity PA SGD-H","LU0130102774.USD":"Natixis Harris Associates US Equity RA USD","LU0130517989.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"R\" INC","BK4588":"碎股","LU0648000940.SGD":"Natixis Harris Associates Global Equity RA SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU0980610538.SGD":"Natixis Harris Associates US Equity RA SGD-H","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU0130518102.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"R\" INC","LU0477156797.USD":"HARRIS ASSOCIATES GLOBAL EQUITY \"RE\" (USD) ACC","LU0477156953.USD":"HARRIS ASSOCIATES US VALUE EQUITY \"RE\" (USD) ACC","BK4121":"生命科学工具和服务","LU0528227936.USD":"富达环球人口趋势基金A-ACC","IQV":"艾昆纬","BK4530":"医药外包概念"},"translate_title":"加拿大皇家银行(RBC)表示，IQVIA预计将受益于2026年人工智能实力的临床试验反弹","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IQV":1.5},"content_text":"IQVIA (IQV) is \"well positioned\" to benefit from a projected rise in clinical trial activity through 2026, due to its large \"proprietary data\" assets, strong pharma relationships, and advantages in real-world evidence and artificial intelligence-driven analytics, RBC Capital Markets said in a report emailed Tuesday.The brokerage cited numerous indicators pointing to an acceleration in clinical trial activity into 2026, signaling an \"inflection\" in the contract research organization market, adding that IQVIA's scale and \"differentiated\" analytics capabilities give it a \"competitive edge\" as activity rebounds.The firm highlighted IQVIA's database of about \"1.2 billion patient records\" and more than 64 petabytes of proprietary data, which it said can enhance clinical trial design, site selection and patient recruitment. As real-world evidence, or RWE, becomes increasingly embedded in clinical studies, RBC believes IQVIA's data advantage will be a key driver of outperformance.RBC initiated coverage of IQVIA with an outperform rating and a $221 price target.Price: 170.38, Change: -3.89, Percent Change: -2.23","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616322583","isCrawlerRequest":true}